Cipla gains 3% post USFDA approval for its generic HIV drug

The stock up 3% at Rs 622 on the BSE in early morning trade and is 6.6% away from its 52-week high of Rs 663 touched on November 7, 2017. Shares of Cipla were up 3% at Rs 622 per share on the BSE in early morning trade after the company said that it has received approval from the US Food and Drug Administration (USFDA) to market Efavirenz tablets, used to treat HIV-1 infections in adults. The stock of pharmaceutical company is 6.6% away from its 52-week high of Rs 663 touched on November 7, 2017 on the BSE..

To Get Free Trial 
Missed call @ 9582541010 
Call Us @ 8822117117 
Mail Us = starindiamarket@gmail.com 
Visit = http://www.starindiaresearch.com/freetrail.php